1,412 results on '"Uemura, Hiroji"'
Search Results
52. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
53. A case of allograft ureteral stone successfully treated with antegrade ureteroscopic lithotripsy: use of a 3D-printed model to determine the ideal approach
54. Complications of ADT for Prostate Cancer: Osteoporosis and the Risk of Fracture
55. Clinical management of nonobstructive azoospermia: An update.
56. Patients’ preference and time to finish injection for GnRH agonist and GnRH antagonist in Japanese prostate cancer patients
57. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
58. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan
59. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
60. Effectiveness and Feasibility of Up-Front Docetaxel Chemotherapy for Japanese Metastatic Hormone-Naïve Prostate Cancer
61. Shared decision making, physicians’ explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients
62. Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
63. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
64. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
65. Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases
66. The impact of smoking on male lower urinary tract symptoms (LUTS)
67. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
68. Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer
69. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
70. The efficacy of microsurgical varicocelectomy as a salvage option for grade 1 varicocele: a retrospective study
71. Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate
72. Negative correlation between presence of reactive oxygen species and Sperm Motility Index in whole semen samples of infertile males
73. Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
74. Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
75. Sperm cryopreservation for fertility preservation in male patients with cancer at a single-center in Japan
76. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma
77. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
78. A Rat Model to Study the Effects of Diet-Induced Obesity on Radiation-Induced Mammary Carcinogenesis
79. Additional file 2 of Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
80. Additional file 1 of Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
81. Successful removal of an encrusted metallic ureteral stent using a disposable ureteroscope and Ho:YAG laser lithotripsy
82. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer
83. Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab
84. Lower urinary tract symptoms are elevated with depression in Japanese women.
85. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study
86. Sperm cryopreservation before definitive therapy for early‐stage prostate cancer: A single institution experience
87. The development and validation of a nomogram and calculator for survival among men treated with abiraterone acetate and/or enzalutamide for metastatic castration-resistant prostate cancer
88. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide
89. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
90. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival
91. Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the J‐ROCK study
92. Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study
93. A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen <10 ng/mL
94. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021
95. Microsurgical varicocelectomy for intratesticular varicocele with a history of orchiopexy for undescended testis
96. Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.
97. Reactive oxygen species measured in the unprocessed semen samples of 715 infertile patients
98. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study.
99. Gastrointestinal cancer and bilateral hydronephrosis resulted in a high risk of ureteral stent failure
100. Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.